Task force 4: Influence of private sector parties on access to cardiovascular care  by DeMaria, Anthony N. et al.
JACC Vnl . 19, No 7
June
1992
:1441-92
•
	
Develop a process for involving and supporting ACC
Chapters in addressing issues relating to cost of and
access to cardiovascular care at the local level . These
might include exploration of more efficient uses of
resources at the local level to avoid ct;slly duplication
of
highly technical services
.
• Provide a forum for the critical analysis of the compo-
nents involved in the increasing volume of cardiovas-
cular services and their cost .
• Encourage innovation and creativity in clinical practice
and technology with safeguards to prevent proliferation
of technology until apprac slate controlled studies have
demonstrated the desirability of widespread utilization .
• Continue education of cardiovascular specialists on
their responsibility to provide access in a cost-effective
manner . This includes the avoidance of utilization of
duplicative technical procedures. The ACC should
encourage regionalization of underutilized, high cost,
technical procedures
.
• Emphasize ethical standards of practice as outlined in
Bethesda Conference 21 : "Ethics in Cardiovascular
Medicine ."
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Introduction
Any discussior of health policy, particularly a consideration
of
access to health care, tends to focus on the actions of
government . However, health-related groups in the private
sector also play an important role in influencing access to
cardiovascular care . Employer groups are of major impor-
tance, because employment is the major source of health
insurance in the United States
. Insurance companies and the
insurance industry in general may profoundly influence
health care, because insurance is the vehicle by which the
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majority of health care coverage in the U .S . is provided .
Medical industries, particularly companies involved with
pharmaceutical agents and medical instrumentation, are a
prominent private sector force capable of influencing health
care delivery. Finally
. organizations involved in liability and
malpractice litigation can also have a substantial impact on
the accessibility of health care . The purpose of this task
force is to consider factors affecting or produced by private
sector health-related groups that can influence access to
cardiovascular care
. This task force will also attempt to
1470
	
DOMAR[A ET AL.
TASK FORCE 4
identify measures that these private sector groups can take
to improve access to cardiovascular care .
Access to cardiovascular care may be viewed in several
ways . First and foremost, of course, attention is drawn to
the more than 30 million uninsured Americans for whom
reduced access to health care is so palpably present . How-
ever, issues also exist with regard to persons who are
underinsured or who have standard health benefits but
whose specific access may be limited by the policies and
procedures of the carrier. Clearly, employers, the medical
technology industry, insurers and those involved in medical
liability all play an important role in determining optimal
access for both the uninsured and the insured .
Role of Business
Health insurance in the U .S . has been traditionally ob-
tahted through the workplace from employers . This is par-
ticaiarly true for persons employed by major corporations
(for example, "Fortune 500" companies) but is much less
applicable to workers in small businesses
. In fact, the
National Medical Expenditure Survey reported that more
than 26% of workers in settings with fewer than 10 employ-
ees were uninsured (1,2). In addition, both considerable
variability in the type of insurance provided by employers
and substantial employee discretion as to which program to
obtain provide significant opportunity for underinsurance .
Recently, increasing costs for health care have stimulated
many businesses to reexamine both their rc!e in and the
current method of providing health care benefits to c . .ploy-
ees . It has been estimated that expenditures for insurance
premiums increased by an average of 24% in 1989 and 14% in
1990 (3) . Health care is now the most rapidly rising portion of
the operating budgets of many corporations, and has been
estimated to be equal to after-tax profits . Not surprisingly,
evidence exists that the number of businesses providing
insurance coverage to their employees is decreasing (4).
Obviously, these measures serve to increase the number of
uninsured or underinsured persons and thereby worsen
access.
In an attempt to achieve maximal return for dollars spent,
payers have begun to manage the care provided to their
beneficiaries by using techniques to determine the need for
and the appropriateness, efficacy and outcome of care . In
principle, this process is directed toward paying for (and
thus providing access to) care that is of benefit, and denying
payment for care that provides no benefit or may even be
harmful . The techniques used include second opinion, pre-
certification and utilization review and are implemented
under the general rubric of "managed care ." By necessity,
in the absence of other treasures, these techniques are
external to the care process that involves an intimate doctor-
patient relation.
These efforts to manage the care provided to employees
are a change from the historic behavior of employers and
insurers, who once simply paid the bills for services pro-
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vided . Many have argued that the managed care process has
reduced the efficiency of the total health care system be-
cause it has increased administrative costs and diverted
revenue from providing additional access . However, those
who have successfully implemented managed care programs
state that the increased administration enables better control
of medical costs, reduced premiums and greater assurance of
quality of care
. At the same time, the managed care process
has made clearly visible the uncertainty attached to the
outcomes achieved by a number of cardiovascular interven-
tions . Indeed, this uncertainty is often highest for proce-
dures that are expensive and frequently utilized . The effect
of the management effort may increase access (for example,
through preventive measures such as immunization) or may
impede access by restricting choice of physician, restricting
direct access to specialists or providing certain types of care
only in conjunction with patient copayment .
As they attempt to control costs with managed care,
many payers are simultaneously implementing continuous
quality improvement programs to provide better care to
beneficiaries. One approach would assign responsibility for
establishing the process by which health care is delivered to
professional societies such as the ACC but would delegate
the determination of quality to individual cardiovascular
specialists at the site of care delivery . System improvement
can be addressed by attempting to classify the components
of care into degrees of certainty for appropriateness . The
generation of guidelines for appropriateness by the ACC
would be of great value to this process . At least in theory, an
element of care that is always appropriate would not require
a second opinion, precertification or utilization review .
Unfortunately, payers currently often have a low level of
confidence about appropriateness of a particular aspect of
care. This leads to questions relating not only to an individ-
ual case and its specifics but also to system improvement .
Alternative methods could be undertaken to assure quality,
such as external audit surveys of the record-keeping accu-
racy and validity of stated outcomes of a representative
sample of a physician's case load . If record keeping were
consistent and criteria for appropriateness scientifically
valid, the need for medical services under these conditions
should be clear and intervention by outsiders minimal .
Where appropriateness was less established, payers might
depend on patient judgment to supplement physician judg-
ment by requiring an appropriate copayment . Some services
not judged by payers to be of value to the individual would
not be included in insurance coverage . Statistical data for
physician, patient and payer would improve the validity of
this process .
Small businesses have unique issues with regard to em-
ployer-provided health benefits and access to care . First, the
costs of health insurance have been estimated to be 20%
greater for small than for large businesses because of higher
administrative costs and other factors (5)
.
Second, although
the costs for employee insurance are totally tax deductible
for large businesses, self-employed persons can deduct only
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25% of health insurance costs from their taxes 16) . As will be
discussed with respect to the insurance industry, small
businesses frequently have their coverage restricted or their
premiums increased because of the medical condition of one
or two persons in the group . Because health care costs for
large employee pools are spread among many persons .
premiums are lower. It is not surprising, therefore . that
two-thirds of employed persons without insurance are drawn
from small businesses (6) .
Several factors were responsible for the evolution of the
central role of employers in the provision of health insur-
ance, and the same mechanisms could be used to enhance
access to care . During the Second World War salaries were
frozen, ana health care benefits were one of the few ways in
which employers could adjust the compensation of their
work force
. Subsequently, classification of health care ben-
efits as tax deductible rendered it preferable to provide
employees with health insurance rather than an equivalent
salary amount . Some modification of the taxes levied on
business for health care benefits could provide a method to
improve access to care . Certainly, a reconsideration of the
tax deductibility for health insurance of self-employed per-
sons is in order.
Mechanisms to ensure the necessity, appropriateness,
efficiency, quality and outcome of care would affect the
access to cardiovascular services that payers provide to their
beneficiaries
. In this regard, it would appear to be of critical
importance to define a package of core benefits for cardio-
vascular patients based on appropriateness; this function
could be filled by the ACC . The definition of such core
benefits would probably form the basis for the support of the
business community for access to health care for its own
employees, as well as extension of such access to society in
general . Industry will certainly be unwilling to support more
generous health care access to a broad public that is unable
to pay for such services than it is willing to provide to its own
employees.
Role of the Pharmaceutical and
Equipment Industry
In the purest sense, access to health care depends on the
existence of effective diagnostic and therapeutic modalities,
and the pharmaceutical and medical equipment industries
thereby provide access to cardiac care by developing and
disseminating innovative technology . However, new and
expensive technology is invariably cited as an important
factor responsible for increasing health care expenditures .
Innovative and improved drugs and medical instrumentation
beget both the benefits of increased health and the liabilities
of increased expenses. Thus, the development of beta-
blockers and calcium channel antagonists to supplement
nitrates in the treatment of angina pectoris, the development
of cholesterol-lowering agents and the implementation of the
automatic implantable cardiac defibrillator stand as exam-
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pies of new cost-effective forms of therapy, made possible
by technical innovation. that have also increased the cost of
health care .
In addition to providing new modalities of health care
where none had previously existed, the development of new
pharmaceutical agents and medical equipment can increase
access to cardiac care in several other ways . New technol-
ogy may provide less complex and more cost-effective
diagnostic and therapeutic modalities, such as the quantifi-
cation of mitral stenosis by ultrasound as compared with
invasive cardiac catheterization . New drugs and instrumen-
tation may replace or reduce the need for surgical therapy of
certain conditions. such as catheter ablation of supraventric-
ular arrhythmias, may enable some patients to be treated as
outpatients and may reduce the need for long-term medica-
tions and the number of follow-up visits . In each case,
resources will be conserved to provide greater access to
care.
It is essential that all new technology undergo evaluation
to document its accuracy and efficacy in diagnosis or ther-
apy. New drugs, instrumentation and procedures should not
be widely used throughout the medical community until such
studies are completed. However, it should be recognized
that technology may be introduced in phases, and may be
initially marketed with a capability that will be expanded or
enhanced over time . In addition to medical accuracy, the
cost-effectiveness of the new technology should be assessed,
particularly in relation to devices capable of similar applica-
tions . .Accardingly, incremental benefit over that of existing
technology should be an important consideration in devel-
oping new techniques, so that optimal utiiizatiun of :: .-fled
resources can be ensured and access to care maximized .
Unfortunately, physician demand for the maximal technol-
ogy possible, even when not most cost-effective, often
serves as a stimulus for industry to provide excessively
costly drugs and devices . In regard to medical technology,
medical industry in conjunction with the ACC could take
steps to ensure that new technology is presented to both
medical and lay audiences in an appropriate context, and not
marketed prematurely or excessively to engender unrealistic
expectations.
Pharmaceutical agents are somewhat unique in the field of
health care in that they have net been included in most prior
cost-containment measures. fact, d:vg prices increased by
152% in the 199s, and rose three times as fast as the rate of
inflation in the first half of 1991 (7). The increase in drug
price has often applied even to long-standing products for
which generic drugs are available
. The drug industry has
been highly profitable
; projected revenues during 1991 were
$63 billion and profits for the 10 largest pharmaceutical
companies were three times that of the average of the
Fortune 500 companies (7) . Moreover, considerable reve-
nues are directed toward marketing or developing agents
that are nearly identical to already available drugs
. The
foregoing considerations have led to scrutiny of the contri-
bution of the pharmaceutical industry to the existence and
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solution of the access problem . It has been suggested that
smaller profits or less money spent for marketing might
enable greater access for patients to pharmacologic agents .
Clearly, a major issue air cling the ability of pharmaceu-
tical and instrumentation companies to maximize access to
health care is the cost of product development . According to
the Pharmaceutical Manufacturers Association, only I of
every 5,000 compounds evaluated becomes a product that
can be marketed . In addition, research costs have doubled
every 5 years since 1970 . Evidence exists that the regulatory
review process for the development of a compound from
synthesis to market entails an average of 12 years and
approximately $200 million in costs (7) . It is obvious that
considerable financial resources would be available to ex-
teid access to health care if this process were shortened and
simplified
.
Recently, medical industry has increased its efforts to
reduce regulatory review times, conduct cost-effectiveness
studies and share the results of research studies . For exam-
ple. CANDA, the Computer-Assisted New Drug Applica-
tion, has been developed and may save more than 20%
of
Food and Drug Administration (FDA) review time . Simi-
larly,
drug companies are providing staff members whose
sole responsibility is to deal one-on-one with FDA review-
ers, an approach that ensures that each reviewer's questions
are handled promptly. These measures should serve to direct
more funds to patient care .
Specific considerations exist with regard to the optimal
cost-efficacy of pharmacologic therapy . Two medications
may differ dramatically in price but minimally or not at all in
benefit. For example, recombinant tissue-type plasminogen
activator and streptokinase are two thrombolytic agents that
have an approximately 10-fold difference in cost, but have
thus far been demonstrated to be of similar benefit in
reducing mortality due to myocardial infarction . The poten-
tial may thus exist to use a less expensive agent without
losing therapeutic benefit and provide additional care with
the money saved . From the standpoint of the formulary,
substitutions of generic drugs may offer considerable cost
savings. In each of the preceding cases, of course, it is of
critical importance that the agent selected he of equivalent
efficacy to the more expensive product . A less expensive
drug or device may be less cost-effective by failing to
achieve the desired result, increasing the number of side
effects or failing to prevent recurrences
. With respect to
instrumentation, it may be desirable to regionalize new
expensive technology that may be indicated in only a small
proportion of cases, rather than to duplicate partially used
facilities at multiple locations .
The pharmaceutical industry could directly and immedi-
ately affect access to cardiovascular care by distributing
drugs at cost or even without charge to indigent patients
.
Several companies have begun efforts to provide free med-
ication to the poor
. Alternatively, pharmaceutical companies
might provide, on a case by case basis, free medication to
persons without funds after identification by a physician or
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pharmacist. Pharmaceutical companies could also enhance
access by supporting long-term outcome research on the
agents they produce or the disorders for which they are
utilized . Although the desirability of sach action is obvious,
it is also clear that drug companies are :^-profit indvstties
and have a fiscal obligation to shareholders- Finally, in the
interests of access, drug companies should seek to provide
prescription drugs at the lowest price possible and to limit
the marketing budget to that which is necessary .
The Medical Liability Problem : Its Impact on
Access to Health Care
Medical liability costs were the fastest growing compo-
nent of physician practice expenses in the 1980s (8) . Average
premiums tripled during this time, far outpacing any measure
of general economic inflation . The frequency of medical
claims also increased dramatically. It is now expected that
38% of all physicians will experience a liability claim at some
time in their career, a proportion that increases to 50% if the
practice includes surgery .
The cost of liability, together with the ubiquitous threat of
litigation, affects patient access to care in four ways : I) it
makes it unaffordable to deliver the full range of health care
services in some situations ; 2) it adds substantially to the
cost
ofall health care services, making them unaffordable for
some patients
; 3) it deprives physicians of certain drugs and
medical devices that could enhance patient care ; and 4) it
undermines the foundation of trust and cooperation that is
fundamental to a successful physician-patient relation .
The Effect of Liability on Availability of
Medical Services
Professional liability costs have been directly linked to
gaps in access to physician services
. The problems appear to
cluster in the areas of obstetric care, emergency room and
community health care center care and rum] health care . The
1987 Department of Health and Human Services Task Force
Report on Medical Liabiply and Malpractice documented
such problems in 26 slates
. Much attention has been focused
on the plight of community and migrant health care centers
whose federal and state funding has not kept pace with
increases in liability premiums
. Access problems are created
when the liability-related cost to health care professionals
and institutions cannot be passed on to patients . This situa-
tion provides an economic incentive to physicians to restrict
practice in fields that carry a higher risk of litigation in
exchange for obtaining a lower premium .
Emergency rooms and community health care centers are
perceived to be settings that carry a higher risk of litigation.
Many physicians believe that more adverse outcomes occur
in such settings because 1) the patients receive poorer
preventive medical care and are on average less healthy than
other groups ; 2) the quality of care is frequently hampered
by insufficient staff and resources ; and 3) the patients are
JACC Vol . 19. No. 7
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harder to treat after discharge . Rural health care settings are
problematic because as the patient volume may not be
sufficient to allow a physician to reasonably spread high
practice costs through fees for medical service . Accordingly .
physicians often choose not to practice in these settings,
thereby diminishing patient access to care .
Many physicians who are retired or have discretionary
time available would like to provide free care to those for
whom it is unaffordable or unavailable . However, medical
liability carriers often refuse to cover such activities . This
practice reduces access to care, and a decision to cover
these services would represent a tangible measure that could
be taken by liability insurers to enhance access .
The Cost Impact of Medical Liability
Even when liability-related costs do not directly cause the
unavailability of health care services, they contribute to the
escalation in the costs of such services. staking them unaf-
fordable for some patients . As previously mentioned, liabil-
ity premiums were the fastest growing component of physi-
cian practice expenses in the 1980s, increasing at an eve : age
annualized rate of 15 .1% (8) . In 1989, such premiums added
$5 .6 billion to the nationwide bill for health care scrvie .s
.
A less apparent liability-related cost is the phenomenon
of "defensive" medicine : those procedures and tests per-
formed by health care providers primarily to enhance defen-
sibility of a medical record. On the basis of annual surveys of
practicing physicians, the American Medical Association
(AMA) estimates that the cost of defensive medicit a was
$15 .1 billion in 1989 (9). When added to premium expenses,
the sum of 1989 physician liability costs was 520 .7 billion or
20% of the estimated cost of physician services in that year
.
Our nation's
poorly
functioning system for resolving
medical liability disputes generates broader social costs that
are borne initially by government, health and disability
insurers, the business community and, ultimately, by con-
sumers and taxpayers. The U .S . civil justice system is the
most expensive dispute resolution system in the world .
Studies by the RAND Corporation (10) suggest that less than
half of every liability premium dollar spent by health care
providers ever reaches an injured patient. The remainder is
absorbed primarily iv dhe cos . ;of resolving disputes, most of
which comprise plain' )f and defense attorney fees . Among
the factors tt,a: p.Wuce these high litigation costs are 1) long
delays in litigation ; 2) excessive discovery procedures; 3) the
almost lotterylike possibility of a huge windfall recovery for
the plaintiff in a sympathetic case : 4) the absence of any
standards regarding the value of noneconomic elements of
damage (e.g., pain and suffering, loss of consortium, loss of
enjoyment of life) . The U .S
. practice of using a jury with
wide latitude in assessing fault and awarding damages has
been cited by several commentators as a fundamental cause
of high litigation expense .
Although our litigation costs are high, they do not buy
consistent or efficient decision making. Separate studies
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conducted in California in 1975 (I I) and New York in 1989
(12) indicated that as few as 1 in 12 patients who are injured
by medical malpractice are ever compensated through the
civil justice system . These patients must seek compensation
and medical care from other sources . At the same time. U .S.
courts appear to be replete with litigation that has no merit.
The New York study (12) indicated that 80% of lawsuits
alleging medical malpractice failed to yield any evidence of
negligence . The U .S . General Accounting Office estimates
that 43% of insurer defense costs are spent on cases that are
eventually closed without a biding of negligence .
The Impact of Product Liability on Access to
Medical Care
The broader social cost implications just examined are
not peculiar to medical liability litigation . However. medical
liability litigation is the type of "high stakes" litigation so
troublesome to policymakers concerned with the. effect of
legal costs on American productivity and competitiveness .
Product liability costs also affect access to health care, by
ii-easing tile cost or inhibiting the availability to i uc,ors . ut
both, of effective drugs and medical devices .
The Effect of Liability Risk on Physician-
Patient Relations
A final aspect of the effect of the problem of liability on
access to care is its impact on the physician-patient relation,
The New York study (12) previously discussed confirmed
that the threat of lawsuits does not seem to correlate with
negligent care. Rather, the distribution of liability claims
appears to signal that every patient is a potential litigant,
whether or riot the physician renders quality care. In addi-
tion to promoting defensive medicine, this phenomenon can
foster an attitude of distrust of patienis toward the physician
community. In fact, physicians often cite an increased risk of
liability claims as a reason for their reluctance to treat
indigent patients, although studies suggest that poor people
are less likely to file a liability claim .
Emerging Trends: Liability Versus
Cost Containment
In an effort to improve access to health care, policymak-
ers and third-party payers are engaged in a manifold attempt
to contain the escalating cost of health care services
. This
process appears to be on a collision course with an emerging
trend in the courts to expand the patient's legal right to an
increased array of health care services
. Two significant cases
illustrate this tension. In Belting vs. Carey (1974), the
Washington Supreme Court found for a plaintiff under age 40
who was not screened for glaucoma, despite a low incidence
of glaucoma and the fact that screening was not the standard
of care. In so doing, it effectively elevated both the standard
and the cost of ophthalmologic care for all patients in the
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state, in exchavce far very marginal improvement in patient
safety. In Wickline vs . State of California (1')86), an insurer
refused to pay for extended hospital stay to ensure that
resolved complications did not reemerge
. The court recog-
nized a potential cause of action "when medically inappro-
priate decisions result from defects in the design or imple-
mentation of cost containment mechanisms ." As these cases
well illustrate, in medical liability cases courts tend to apply
a patient-oriented standard of care in hindsight that does not
easily accommodate the social goal of cost containment .
Liability Reform Proposals
Medical liability tort reform may ameliorate problems of
access to care in various ways. Many different reform
proposals have been made . Once almost exclusively within
the province of state legislation, medical liability reform
increasingly is the focus of federal reform legislation.
Reforms that help to contain the cost of physician liability
premiums are likely to slow the escalating cost of health care
services. In California, for example, physician liability pre-
miums have stabilized at about one-third less than the cost of
premiums in states without meaningful reform . The core of
the California reform model consists of 1) a ceiling on
noneconomic damages : 2) sliding scale regulation of attorney
eontinorncy fees (the fee as a percentage of the awarded
damages decreases as the size of the award increases) ;
3) mandatory periodic payment of future elements of dam-
age ; and 4) an offset from the award for reimbursement from
"collateral sources" such as health insurance and disabi!'ty
insurance . On the basis of California's experience, several
federal medical liability bills have been introduced that
would extend this reform package nationwide, an extension
that the ACC should aggressively support .
Reforms that shorten the time or improve the cost-
effectiveness, or both, of the dispute resolution process have
the potential to help stabilize medical liability costs. Several
alternative dispute resolution models have been proposed,
such as binding arbitration and no-fault compensation sys-
tems. Proponents of these models argue that resolving
claims more expeditiously with less transaction cost will
funnel more net compensation to victims of malpractice,
thereby reducing the impact of liability on the broader social
concerns of productivity and competitiveness . Few of these
models have actually been implemented.
Some reform proposals, including two federal bills, are
based on practice guidelines . These proposals advocate that
such guidelines, developed by organized medicine or gov-
ernment, be made equivalent to the legal standard of care
applied in medical Liability cases . Proponents argue that this
action would eliminate defensive medicine costs and assert
that because substantive guidelines would be available for
opposing parties and the jury, the result might be a shorter
period of litigation and lower transaction costs . The gener-
ation of guidelines is an area in which ACC can make a
substantial contribution to access
.
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Efforts to reform medical liability must be accompanied
by equivalent efforts to identify and reduce the amount of
actual malpractice. The College should study or support
studies concerning the relation between malpractice and
unnecessary or inappropriate procedures . In addition, the
College should take an active role in the medical community
to identify physicians who are impaired or incompetent and
develop mechanisms for intervention and education, or for
censure if these measures have failed.
As the various proposals to achieve health care access
and reimbursement reform go forward, attention to reform of
the medical liability system must be part of the deliberation.
Although liability reform is not the single answer to the
multitude of access to health care problems, it must be part
of any solution that hopes to be successful .
The Role of Health Insurance
Since its inception, private health insurance has grown to
cover more than 80% of the population or almost 200 million
Americans today (5) . During the first 45 years, the growth
was primarily in traditional indemnity type insurance con-
tracts . Howeverr with the passage of the Federal Health
Maintenance Organization (HMO) Act, in the mid 1970s,
there has been a dramatic growth in HMO membership, from
fewer than 6 million persons in 1975 to more than 35 million
by 1990 . Thus, the insurance industry is of fundamental
importance in determining access to health care in the U
.S.
Over the course of 50 years, the expectations from
insurance have changed. In 1940, when national health
expenditures stood at $4 billion or 4% of the gross national
product, health insurance was simply a convenient prepay-
ment mechanism. During the war years and through the
1950s and 1960s . health insurance became an important
fringe benefit, a means of compensation to attract, motivate
and retain good employees . Full payment of medical bills
and hassle-free claims service were the marks of a good
insurer. In the last 3 years as national health expenditures
crept past $600 billion and 12% of the gross national product,
management of health care costs (cost containment) has
become the dominant corsvmel demand .
Benefit Provisions
Almost from the beginning, health insurance policies
covered the cost of hospital and physician services
. Most
deductibles and coinsurance were subsequently introduced
as a way to limit administrative expenses, reduce employer
costs and foster cost consciousness on the part of employ-
ees . As the health care delivery system expanded, a series of
ancillary services and providers were mandated by legisla-
tion to be included in insurance contracts . Today in various
states there are some 800 separate mandated coverages that
add substantially (estimates range to 15%) to the cost of
coverage. The proliferation of benefits and the inconsistency
among state requirements have complicated the administra-
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tinn of plans for both insurers and providers . increased
administrative costs and diminishes access by resulting in
increased prices for coverage .
Renefrt Limitations
Three provisions in insurance ' ontracts that limit health
benefits have been the focus of c( •nsiderable debate . These
relate to 1) preexisting conditions, 2) medical necessity . and
3) experimental procedures . Limitations on preexisting con-
ditions typically deny enroltmen or require that a person
have been insured fur 6 or 12 months before payment is
made for medical conditions that exist at the time that
insurance is activated . Although initially intended to prevent
the acquisition of insurance only after the onset of illness,
this provision has excluded many persons from coverage .
even some with problems such as mild hypertension . More-
over, the provisions may also prevent persons who have had
an illness, or whose dependents have had an illness, from
ehangingjobs or reacquiring insurance after!osing a job . The
ACC should vigorously support guaranteed availability and
renewability of health care coverage for all Ame-icon' The
goal of the College should be to eliminate financial barriers tc
health care coverage and to create a 'lose of security in
Americans that their health care needs will be met .
Medical necessity is the criterion that insurers initially
employed to discourage frivolous use of the health care
system. Today, it has been used by insurers to question the
appropriateness of certain treatments and thereby deny
payment. The development of more precise diagnostic and
treatment guidelines will help to eliminate the controversy
that surrounds the application of he criterion of medical
necessity . The limitation on experimental procedures (such
as bone marrow transplantation) is also controversial . The
issue is whether insurers, in contracting with individual
patients or employers, usswne a social or moral resvonsibil-
ity for paying for any and all services that might benefit the
patient, or whether the law of contracts allow insurers to
limit payment to those services specifically identified in the
contract itself. These three limitations greatly affect the cost
of health insurance policies and should be addressed in an
attempt to maximize access to care .
Both medical necessity and experimental treatment limi-
tations have a significant impact on cardiac care . Most
insurance policies cover a wide range of common cardiac
procedures. For insurers, the issue is not whether the
technology is proved and effective, but whether it is appro-
priate for a particular patient
. Cardiologic care tends to be
more procedure oriented and invasive than the care provided
by many specialties . The morbidity and mortality risks
associated with this care are higher than those of many other
specialties and as a result receive more than the usual
attention from insurance company and managed care medi-
cal directors and claims reviewers . The importance of de-
veloping wractice guidelines and developing ongoing working
relations between the profession and the industry cannot be
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overemphasized as away of avoiding confusion end disputes
about coverage.
As the managed care movement expanded, the use of
centers of excellence increased. Heart transplantation is
frequently performed in these centers, and transplant pa-
tients are typically referred to one of the centers for surgery .
Most of the larger companies employ a rather exhaustive
screening process to identify centers of excellence . Individ-
ual facilities seeking to perform transplantation will be
evaluated in terms of total volume . survival rates, retrans-
plantation rates as well as the presence of good social service
systems to accommodate the needs of family members .
Managed Care
As indicated previously, the health care reimbursement
systems are rapidly moving away from indemnity fee for
service toward a managed care environment . As recently as
1982, 95% of all reimbursement was handled on a fee for
service basis. In this setting the patient had freedom of
choice of physician, who in turn had nearly unrestricted
freedom to perform diagnostic and therapeutic procedures .
By 1989 . less than 30% of reimbursement remained in a pure
fee for service mode. Most health care economists are
predicting that by 1994 70% of the market will be represented
by network-based plans that require either an annual con-
tract with designated providers or point of service choice,
and that less than 10% of the market will be unmonitored fee
for service reimbursed programs
. A major concern in this
transition is to ensure that negative incentives to provide
service in any such programs do not
reduce
access to
necessary and beneficial cardiac care .
Managed care is not a well understood term
. Utilization
review, preadmission certification, second opinion for sur-
gical procedures and procedure review are all techniques
that are used in managed care programs . However, true
managed care programs are network based and have the
following characteristics : arrangements with selected pro-
eiders to furnish a comprehensive set of health care services
to members : explicit standards for the selection of health
care providers; formal programs for ongoing quality assur-
ance and utilization review, and significant financial incen-
tives for members to use providers and procedures associ-
ated with the plan .
In determining the provisions of a health care program,
employers want to contain costs and still provide employee
satisfaction. Containing costs usually means managing an
individual patient's use of the health care system, whereas
the greatest employee satisfaction usually means complete
freedom of choice
. Many employers are opting for some-
thing between the two extremes but are clearly moving
toward a more structured system . A common compromise is
a point of service choice program
. The employee who stays
within the network will have virtually all of these costs
reimbursed, whereas the employee who opts for treatment
outside the network must pay a significant deductible and a
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higher level of coinsurance . Although freedom of choice
remains a clear option, the incentives to stay within the
network are very strong . Again, it is crucial that such
incentives do not deny beneficial care to patients .
Several specific issues are prominent with regard to the
insurance process and the more than 30 million Americans
who are uninsured . As discussed previously, insurance
coverage for small businesses is both limited and expensive .
Employees of small businesses are subject to more medical
testing of applicants, exclusions and denials of coverage (4) .
These problems arc accentuated for those seeking individual
insurance, who often are perceived as persons at high risk
requiring large administrative costs . Clearly these are impor-
tant issues to address in assuring optimal access to health
care . The ACC should vigorously support the implementa-
tion of a system of health care coverage that is seamless,
portable and affordable for all Americans
.
The configuration of the insurance industry is another
important issue relating to access. At present there are
approximately 1,500 insurance companies in the U .S., ac-
counting for a multiplicity of policies, procedures and forms
(13). This configuration imposes an enormous expense and is
burdensome and costly for both patients and physicians . It
would appear that access to health care could be substan-
tially increased if there were greater uniformity, and perhaps
consolidation, among insurance companies .
Recommendations
The ACC should rake a number of direct and indirect
actions to assist the private sector in achieving optimal
access to care. It should:
• Continue, as recommended in Task Force 3, to develop
guidelines for the appropriate practice of cardiology,
thereby defining for employers those aspects of cardio-
vascular practice that are
appropriate,
necessary and of
high quality . Such guidelines should serve to reduce
actions related to defensive medicine, diminish unwar-
ranted medical liability claims and reduce the likeli-
hood of nonpayment for medical services based on the
medical necessity criterion .
• Be cognizant of the guideline development process of
both the AMA (14) and the Institute of Medicine (15)
and conduct its procedures appropriately . The ACC
should interface with the Agency for Health Care
Policy and Research (AHCPR) in guideline develop-
ment, as they are charged by Congress under the
Omnibus Budget Reconciliation Act of 1989 to "ar-
range for the development and periodic review and
updating of clinically relevant guidelines . . . ."
• Take steps to ensure that persons representing a broad
spectrum of interests are available for the generation of
guidelines, and that the guidelines are widely used and
result in improved patient outcomes . Demonstration of
this process will enhance patient and payer trust .
• Augment its activities with regard to technology assess-
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merit. This will enable available resources to be de-
voted only to technology of proved efficacy, will be of
value to employers and insurers in determining benefits
packages and will assist the medical instrumentation
industry in the process of technology development .
• Consider approaches by which individual physicians
could assist drug distribution to indigent persons to
enhance access to pharmaceutical agents .
• Take an active role in helping the pharmaceutical
industry to pursue cost-effective marketing .
• Assume a leadership position in ensuring that the true
medical liability risk for caring for low income patients
in emergency rooms and community health care clinics
is understood by cardiovascular specialists .
• In conjunction with the overall medical community and
all of its members, support a process by which impaired
or incompetent physicians are identified and receive
appropriate intervention .
• Continue interaction with the insurance industry in
projects such as the definition of the insurability and
employability of patients with cardiovascular disease .
The ACC
can facilitate access to health care by
fostering certain practices
. It Can
• Foster cost-effective cardiovascular behavior among its
members and exhort its members to use the least expen-
sive equivalent diagnostic or therapeutic modalities.
• Assume a leadership position in ensuring that appropri-
ate new medical advances are communicated to the
public in a responsible fashion.
• As the professional society for cardiovascular special-
ists, exert its considerable influence in restraining ex-
cessive enthusiasm for, and therefore inappropriate
expectations from, new technologic developments .
•
Urge the regionalization of experimental or compli-
cated, high cost, infrequently used technologies .
The College can also seek
to increase access to
health care by serving as advocate to
governmental
and private sector agencies on behalf of certain
health
care policies. It should :
• Be a vigorous spokesman on behalf of the concept of
rationalization of taxes on businesses for health care
benefits.
• Actively support a streamlined process for drug devel-
opment and evaluation on the part of the FDA .
•
Continue its substantial activities on behalf of medical
liability reform. The College should vigorously endorse
1) a ceiling on noneconomic damages ; 2) sliding scale
regulation of ^' xney coning. y fees; 3) mandatory
periodic payment of future ale . ._ its of damages, and
4) an offset from awards r collateral sources .
•
Explore with the legal community alternative ways of
resolving medical liability .
•
Advocate insurance reform by measures to decrease
administrative costs and eliminate denial of insurance
to high risk persons .
IACC Vol
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• Vigorously advocate the implementation of a health
care system that is universal, portable, and renewable .
• Urge liability insurance carriers or state legislators
through good Samaritan laws to cover physicians who are
willing to provide care to those for whom it is unavailable .
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Task Force 5: Access to Cardiovascular Care : An
International Comparison
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Introduction
Wennberg and Gittelsohn (1) have demonstrated variability
in clinical practice patterns, resulting in variable access to,
or rates of, a variety of medical services and procedures .
There is also variation in access to and numbers of services
and procedures among countries, presumably related to the
health delivery system, average per capita income and the
cultural, political and social attitudes of different countries
(2).
This report briefly outlines the health delivery systems
and access to cardiovascular services in eight countries
(Australia, Belgium, Canada, Germany, Japan, the Nether-
lands, Sweden and the United Kingdom) and compares the
data obtained from these countries with that available for the
United States. As a July 1991 article (3) in "The Economist"
pointed out, "There are lessons to be learned from looking at
different ways
of paying for and delivering the goods,
Instead of each country trying out its own experiments, they
should be studying each other's for ideas and pitfalls."
The comparison of data among countries is difficult at
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best, an: impossible at worst, because of the variability of
accuracy of the data, and the difficulty in controlling for
social, medical, cultural, demographic, economic, and pol-
icy differences among countries
(4)- In this Task Force
report we have attempted to collect data directly from
cardiovascular specialists. Whenever possible, these data
have been substantiated through government, the Organiza-
tion for Economic Cooperation and Development (OECD),
or World Health Organization (WHO) data collections . We
have not included outcome data ; there have been no studies
to date that have demonstrated a relation between quality of
life and expenditures on cardiovascular services. We have
not attempted to pass judgment, nor to determine the med-
ical appropriateness or effectiveness, or cost-effectiveness of
the data or the systems generating them .
A brief description of the country and health delivery
systems, with specific reference to the cardiovascular serv-
ices available, is listed for the eight countries in alphabetical
order. Comparisons of collected data are expressed in Ta-
bles I and 2 and Figures I to 11, which follow the descrip-
tions of
the countries-
